Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.

Abstract

BACKGROUND/AIM:

To study the long-term clinical efficacy and tolerability of ibrutinib monotherapy in real-world relapsed and refractory chronic lymphocytic leukemia (RR-CLL) patients outside clinical trials.

PATIENTS AND METHODS:

Clinical data of 171 RR-CLL patients treated with ibrutinib were collected within the observational study of the Polish Adult Leukemia Study Group.

RESULTS:

Median patient age was 64 years. Patients were pretreated with 3 (1-10) median lines of therapy, while 42 (24.6%) had 17p deletion. The median observation time was 40 months (range=1-59 months), while median ibrutinib monotherapy reached 37.5 months (range=0.4-59.2 months). Response was noted in 132 (77.2%) patients. The estimated 5-year progression-free survival (PFS) and overall survival (OS) rates were 61.1% (95%CI=49.3-70.9%) and 56.8% (95%CI=45.6-66.6%), respectively. At the time of analysis 97 (56.7%) remained under ibrutinib monotherapy.

CONCLUSION:

Ibrutinib is clinically effective and tolerable as a monotherapy in real-world RR-CLL patients.

• Authors: Bartosz Pula, Elzbieta Iskierka-Jazdzewska, Monika Dlugosz-Danecka, Agnieszka Szymczyk, Marek Hus, Agnieszka Szeremet, Joanna Drozd-Sokolowska, Anna Waszczuk-Gajda, Jan M Zaucha, Jadwiga Holojda, Weronika Piszczek, Pawel Steckiewicz, Malgorzata Wojciechowska, Michal Osowiecki, Wanda Knopinska-Posluszny, Marek Dudzinski, Daria Zawirska, Edyta Subocz, Janusz Halka, Andrzej Pluta, Ryszard Wichary, Beata Kumiega, Bozena K Budziszewska, Wojciech Jurczak, Ewa Lech-Maranda, Krzysztof Giannopoulos, Tadeusz Robak, Krzysztof Jamroziak
• Journal: Anticancer research (Anticancer Res) Vol. 40 Issue 7 Pg. 4059-4066 (Jul 2020) ISSN: 1791-7530 [Electronic] Greece
• PMID: 32620653 (Publication Type: Journal Article, Observational Study)
• Copyright: Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Antineoplastic Agents
• Piperidines
• Protein Kinase Inhibitors
• Pyrazoles
• Pyrimidines
• ibrutinib
• Adenine

Topics

• Adenine (analogs & derivatives)
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (adverse effects, therapeutic use)
• Drug Resistance, Neoplasm
• Female
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, mortality)
• Male
• Middle Aged
• Piperidines
• Poland
• Protein Kinase Inhibitors (adverse effects, therapeutic use)
• Pyrazoles (adverse effects, therapeutic use)
• Pyrimidines (adverse effects, therapeutic use)
• Recurrence
• Survival Analysis
• Treatment Outcome